These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 10676664

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H.
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.
    Urol Oncol; 2005 Apr; 23(1):16-21. PubMed ID: 15885578
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
    Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M.
    Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
    [Abstract] [Full Text] [Related]

  • 17. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM, Finne P, Leinonen J, Stenman UH.
    Scand J Clin Lab Invest Suppl; 2000 May; 233():51-8. PubMed ID: 11317942
    [Abstract] [Full Text] [Related]

  • 18. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N, Ohyama C, Habuchi T.
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [Abstract] [Full Text] [Related]

  • 19. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP, Tournel C, Michel S, Dalbon P, Jolivet M.
    Electrophoresis; 1999 Feb; 20(4-5):1075-81. PubMed ID: 10344287
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.